Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$8.01
-1.1%
$8.00
$6.10
$28.67
$555.73M1.41395,899 shs49,673 shs
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$9.77
$0.49
$2.60
$2.35B1.5539,610 shs3.45 million shs
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
$43.00
$1.19B1.7710,339 shsN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.23
$0.06
$1.35
$1.87M2.183.66 million shs29.90 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$32.33
-2.0%
$32.01
$26.74
$46.00
$2.48B1.1635,346 shs128,914 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
+1.13%+8.96%-6.37%+20.75%-61.49%
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%+1.89%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00%0.00%0.00%0.00%-91.32%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+0.92%-4.97%+2.55%+5.03%-16.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
4.0562 of 5 stars
4.44.00.00.01.74.20.6
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.181 of 5 stars
4.52.00.00.02.02.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
2.70
Moderate Buy$25.00212.30% Upside
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
0.00
N/AN/AN/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00
N/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00
N/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$54.8269.58% Upside

Current Analyst Ratings Breakdown

Latest BCYC, VBIV, BLUSF, XENE, and CALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $53.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
5/7/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
5/5/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.00
5/5/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.00
5/2/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$35.28M15.71N/AN/A$11.48 per share0.70
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$30K0.00N/AN/A$0.25 per share0.00
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$1.60B0.74N/AN/A$1.06 per share37.74
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$9.41M0.00N/AN/A$0.32 per share0.00
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$9.43M263.02N/AN/A$9.90 per share3.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/14/2025 (Estimated)

Latest BCYC, VBIV, BLUSF, XENE, and CALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.95N/AN/AN/A$9.43 millionN/A
5/12/2025Q1 2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million
5/1/2025Q1 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/A
14.86
14.86
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/A
13.87
13.87
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
9.44
2.69
2.59
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.34
0.21
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
17.66
17.66
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
24069.25 million53.40 millionOptionable
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
10159.12 millionN/ANot Optionable
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
18029.79 million29.14 millionOptionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
2228.68 million25.71 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21076.73 million72.50 millionOptionable

Recent News About These Companies

Xenon Appoints CEO Ian Mortimer as Interim CFO
Xenon Joins the Russell 3000® and Russell 2000® Indexes

Media Sentiment Over Time

Bicycle Therapeutics stock logo

Bicycle Therapeutics NASDAQ:BCYC

$8.01 -0.09 (-1.05%)
As of 12:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BELLUS Health stock logo

BELLUS Health OTCMKTS:BLUSF

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Calliditas Therapeutics AB (publ) stock logo

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)
As of 07/10/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

VBI Vaccines stock logo

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$32.33 -0.66 (-1.99%)
As of 12:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.